Research Topics
| K RickelsSummaryAffiliation: University of Pennsylvania Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled studyOlga Brawman-Mintzer
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC 29406, USA
J Clin Psychiatry 67:874-81. 2006..This study assessed the efficacy and safety of sertraline in the treatment of generalized anxiety disorder (GAD)...
Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trialKarl Rickels
Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
J Clin Psychopharmacol 28:235-9. 2008..Collectively, these results support further clinical investigation of higher doses of PRX-00023 in anxiety and depression...
Physician Withdrawal Checklist (PWC-20)Karl Rickels
Mood and Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
J Clin Psychopharmacol 28:447-51. 2008..Our results suggest that the Penn Physician Withdrawal Checklist is a simple and accurate method to assess anxiolytic discontinuation symptoms...
Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trialKarl Rickels
Department of Psychiatry, Mood and Anxiety Disorders Section, University of Pennsylvania, Philadelphia, PA 19104 3309, USA
J Clin Psychiatry 70:326-33. 2009..The efficacy and tolerability of vilazodone, a combined selective serotonin reuptake inhibitor and partial 5-hydroxytryptamine-1A (5-HT(1A)) receptor agonist, were evaluated in adult patients with major depressive disorder (MDD)...
Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatmentKarl Rickels
Department of Psychiatry, Mood and Anxiety Disorders Section, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Int Clin Psychopharmacol 27:142-50. 2012..3%). The study was discontinued early after an interim analysis. The results indicate that adjunctive pregabalin is an efficacious therapy for patients with GAD who experience an inadequate response to established treatments...
Consumer advertising can be misleadingKarl Rickels
PLoS Med 3:e119; author reply e116. 2006
Assessment of anxiety and depression in primary care: value of a four-item questionnaireMichael R Rickels
Mood and Anxiety Disorders Section, Department of PsychiatryUniversity of Pennsylvania School of Medicine, 3535 Market St, Philadelphia, PA 19104 3309, USA
J Am Osteopath Assoc 109:216-9. 2009..However, such survey tools are typically lengthy and are therefore not used often in primary care...
What is generalized anxiety disorder?K Rickels
Department of Psychiatry, University of Pennsylvania, Philadelphia 19104, USA
J Clin Psychiatry 62:4-12; discussion 13-4. 2001..The impact of the changes in diagnostic criteria on research into GAD, and on diagnosis, differential diagnosis, and treatment of GAD, will be discussed...
Pharmacotherapy of generalized anxiety disorderKarl Rickels
Department of Psychiatry, University of Pennsylvania, Philadelphia, USA
J Clin Psychiatry 63:9-16. 2002..Remission rates are still only about 40%, signifying the need for improved treatment interventions...
A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorderKarl Rickels
Department of Psychiatry, University of Pennsylvania Medical Center, Philadelphia, PA 19104 3309, USA
J Clin Psychopharmacol 24:488-96. 2004..Venlafaxine ER was safe, well tolerated, and efficacious in the short-term treatment of generalized social anxiety disorder...
Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolamKarl Rickels
Department of Psychiatry, University of Pennsylvania, Philadelphia 19104 3309, USA
Arch Gen Psychiatry 62:1022-30. 2005..Pregabalin inhibits release of excess excitatory neurotransmitters, presumably by binding to the alpha2-delta subunit protein of widely distributed voltage-dependent calcium channels in the brain and spinal cord...
Alprazolam extended-release in panic disorderKarl Rickels
University of Pennsylvania, Department of Psychiatry, University of Pennsylvania Medical Center, PA 19104 3309, USA
Expert Opin Pharmacother 5:1599-611. 2004..It should be noted that long-term therapy with alprazolam-XR carries the same risk of dependence and withdrawal during discontinuation as the original formulation of alprazolam...
Overview and clinical presentation of generalized anxiety disorderK Rickels
Section of Mood and Anxiety Disorders, Department of Psychiatry, University of Pennsylvania School of Meidicine, Philadelphia, USA
Psychiatr Clin North Am 24:1-17. 2001..7. Symptoms that some clinicians consider cardinal for a diagnosis of GAD, such as extreme worry, obsessive rumination, and somatization, also are present in other disorders, such as MDD. (ABSTRACT TRUNCATED)..
Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapyK Rickels
Department of Psychiatry, University of Pennsylvania, Philadelphia, USA
Am J Psychiatry 157:1973-9. 2000..5 years) were enrolled in a benzodiazepine discontinuation program that assessed the effectiveness of concomitant imipramine (180 mg/day) and buspirone (38 mg/day) compared to placebo in facilitating benzodiazepine discontinuation...
Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended releaseKarl Rickels
Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, 19104, USA
Arch Gen Psychiatry 67:1274-81. 2010..Generalized anxiety disorder (GAD) is a chronic disorder in need of reliable data to guide long-term treatment...
Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trialKarl Rickels
Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
J Clin Psychopharmacol 30:18-24. 2010..To compare the efficacy and safety of desvenlafaxine (administered as desvenlafaxine succinate) with placebo in reducing relapse rate in patients with major depressive disorder (MDD)...
Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorderK Rickels
Psychopharmacology Unit, University Science Center, University of Pennsylvania 19104 2649, USA
Am J Psychiatry 157:968-74. 2000..This study evaluated the efficacy and safety of fixed doses of once-daily extended-release (XR) venlafaxine in outpatients with generalized anxiety disorder without concomitant major depressive disorder...
Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trialE W Freeman
Department of Obstetrics Gynecology, School of Medicine, University of Pennsylvania, Philadelphia 19104, USA
Arch Gen Psychiatry 56:932-9. 1999....
Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuationK Rickels
Department of Psychiatry, University of Pennsylvania, Philadelphia
Arch Gen Psychiatry 47:899-907. 1990..These results provide a detailed picture of the symptoms, time course, and multidimensional determinants of the benzodiazepine withdrawal syndrome...
Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspironeK Rickels
Department of Psychiatry, Psychopharmacology, University of Pennsylvania, Philadelphia
Arch Gen Psychiatry 45:444-50. 1988..For the buspirone group, a higher dropout rate raised questions about patient satisfaction with therapy in this rather chronically anxious population...
The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trialE Schweizer
Department of Psychiatry, University of Pennsylvania, Philadelphia 19104-3309, USA
Int Clin Psychopharmacol 16:137-43. 2001..While some patients clearly benefit from higher doses, the results of the current study are consistent with the lack of any evidence for a dose-response curve with sertraline in the treatment of depression...
Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trialMoira Rynn
University of Pennsylvania, Philadelphia, Pennsylvania, USA
Depress Anxiety 25:182-9. 2008..Duloxetine was an efficacious, safe, and well-tolerated treatment that resulted in clinically significant improvements in symptom severity and functioning for patients with GAD...
Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressantE W Freeman
Department of Obstetrics Gynecology, University of Pennsylvania Medical Center, Philadelphia 19104, USA
J Clin Psychopharmacol 19:3-8. 1999....
Clorazepate and lorazepam: clinical improvement and rebound anxietyK Rickels
Department of Psychiatry, University of Pennsylvania, Philadelphia
Am J Psychiatry 145:312-7. 1988..The clinical relevance of these findings is discussed...
Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled studyKarl Rickels
Department of Psychiatry, University of Pennsylvania Medical Center, Philadelphia 19104-3309, USA
Am J Psychiatry 160:749-56. 2003..Both doses of paroxetine were well tolerated. CONCLUSIONS: This study demonstrates that paroxetine is an efficacious and well-tolerated treatment for generalized anxiety disorder...
Characteristics of placebo responses in medical treatment of premenstrual syndromeE W Freeman
Department of Obstetrics Gynecology, University of Pennsylvania Medical Center, Philadelphia 19104, USA
Am J Psychiatry 156:1403-8. 1999..This study characterizes the responses to placebo medication of patients with premenstrual syndrome (PMS) who were randomly assigned in controlled treatment trials. Possible predictors of placebo response were also examined...
Paroxetine in the treatment of generalised anxiety disorderSteven H Snyderman
Mood and Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania School of Medicine, 3535 Market Street, Suite 670, Philadelphia, PA 19104, USA
Expert Opin Pharmacother 5:1799-806. 2004....
Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorderM A Rynn
Mood and Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
Am J Psychiatry 158:2008-14. 2001..The study compared the safety and efficacy of sertraline, a selective serotonin reuptake inhibitor, and placebo in the treatment of generalized anxiety disorder in children and adolescents...
Reliability and validity of a daily diary for premenstrual syndromeE W Freeman
Department of Psychiatry, University of Pennsylvania Medical Center, Philadelphia 19104 4283, USA
Psychiatry Res 65:97-106. 1996..The moderate correlations of the DSR with other standard symptom measures add to the evidence that PMS overlaps with other mood disorders at the premenstrual time but is not simply a brief depression or a truncated anxiety disorder...
Clinical overview of serotonin reuptake inhibitorsK Rickels
Department of Psychiatry, University of Pennsylvania, Philadelphia
J Clin Psychiatry 51:9-12. 1990..Although serotonin reuptake inhibitors have not replaced the tricyclics, they are a useful addition to the variety of drugs currently used for the treatment of depression...
Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trialAlan D Feiger
Department of Psychiatry, University of Colorado School of Medicine, Denver, CO, USA
J Clin Psychiatry 67:1354-61. 2006..This study investigated the efficacy, safety, and tolerability of the selegiline transdermal system (STS) administered in a dose range of 6 mg/24 hours to 12 mg/24 hours for treating major depressive disorder (MDD)...
Venlafaxine in the treatment of premenstrual dysphoric disorderE W Freeman
Department of Obstetrics Gynecology, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
Obstet Gynecol 98:737-44. 2001..To evaluate the efficacy and safety of venlafaxine, a new-generation antidepressant that selectively inhibits serotonin and norepinephrine reuptake, in the treatment of premenstrual dysphoric disorder (PMDD)...
Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind studyFalk W Lohoff
Mood and Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
J Clin Psychopharmacol 30:185-9. 2010....
A survey of patient acceptability of repetitive transcranial magnetic stimulation (TMS) during pregnancyDeborah R Kim
Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, United States
J Affect Disord 129:385-90. 2011..Given the novelty of TMS, we sought to assess whether patient acceptability would be a barrier to enrolling pregnant women in TMS studies...
Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorderEllen W Freeman
Department of Obstetrics Gynecology, University of Pennsylvania School of Medicine, Philadelphia 19104 5509, USA
Am J Psychiatry 161:343-51. 2004....
Core symptoms that discriminate premenstrual syndromeEllen W Freeman
Department of Obstetrics Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA
J Womens Health (Larchmt) 20:29-35. 2011..To identify core symptoms that discriminate premenstrual syndrome (PMS) in prospective daily diary ratings and determine the association of these symptoms with functional impairment...
Desvenlafaxine succinate for the treatment of major depressive disorderFalk W Lohoff
University of Pennsylvania School of Medicine Mood and Anxiety Disorders Section, Department of Psychiatry, Center for Neurobiology and Behavior, Translational Research Laboratories, Philadelphia, PA 19104, USA
Expert Opin Pharmacother 9:2129-36. 2008..Additional studies, in particular head-to-head comparison to other antidepressants and long-term treatment studies, will be necessary to comprehensively evaluate DVS safety and efficacy for clinical practice...
Time to relapse after short- or long-term treatment of severe premenstrual syndrome with sertralineEllen W Freeman
Department of Obstetrics Gynecology, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104 5509, USA
Arch Gen Psychiatry 66:537-44. 2009..The duration of treatment after achieving a satisfactory response is unknown in the treatment of premenstrual syndrome. This information is needed in view of the improvement provided by medication vs the adverse effects and costs of drugs...
Remission of generalized anxiety disorder: a review of the paroxetine clinical trials databaseKarl Rickels
Mood and Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania, 3535 Market Street, Philadelphia, PA 19104 3309, USA
J Clin Psychiatry 67:41-7. 2006..This article reviews the efficacy and tolerability of paroxetine in the short- and long-term treatment of GAD including remission data...
Allopregnanolone levels and symptom improvement in severe premenstrual syndromeEllen W Freeman
Department of Obstetrics Gynecology, University of Pennsylvania, Philadelphia 19104, USA
J Clin Psychopharmacol 22:516-20. 2002....
Imipramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapyMoira Rynn
Mood and Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104 3309, USA
J Clin Psychopharmacol 23:505-8. 2003..Neither discontinuation severity nor taper-free status 12 weeks posttaper differed between the 3 treatment groups...
Early response and 8-week treatment outcome in GADMoira Rynn
Mood and Anxiety Disorders Section, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
Depress Anxiety 23:461-5. 2006..001). Early improvement was a strong predictor for treatment outcome irrespective of whether active medication or placebo was the treatment agent...
Abnormal salivary cortisol levels in social phobic patients in response to acute psychological but not physical stressP M Furlan
Department of Psychiatry, Behavioral Psychopharmacology Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6140, USA
Biol Psychiatry 50:254-9. 2001..These results suggest adaptation of distinct biological processes specific to different stressful conditions in social phobia...
A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorderAmir Garakani
Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10075, USA
Int Clin Psychopharmacol 23:269-75. 2008..The combination of quetiapine and fluoxetine, however, improved sleep over fluoxetine alone over the first few weeks of treatment...
Open-label pilot study of ziprasidone for refractory generalized anxiety disorderSteven H Snyderman
J Clin Psychopharmacol 25:497-9. 2005
A pilot naturalistic follow-up of extended sertraline treatment for severe premenstrual syndromeEllen W Freeman
J Clin Psychopharmacol 24:351-3. 2004
Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled studyBoadie W Dunlop
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1841 Clifton Road NE, Atlanta, GA 30307, USA
J Clin Psychopharmacol 27:614-9. 2007..Previous studies suggest that adjunctive modafinil treatment provides benefit for patients with depression with significant sleepiness and fatigue...
The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled studyMark H Pollack
Anxiety Disorders Program, Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital, Simches Research Building, 185 Cambridge Street, Boston, MA 02114, USA
J Clin Psychiatry 66:1401-8. 2005..To evaluate the efficacy and tolerability of tiagabine, a selective gamma-aminobutyric acid (GABA) reuptake inhibitor, in adults with generalized anxiety disorder (GAD)...
Research Grants
- Short-Term vs Long-Term Treatment for GADKarl Rickels; Fiscal Year: 2007..12 months). The proposed study will provide much needed data, lacking from the literature, about the value of long term medication treatment of patients with a DSM-IV GAD diagnosis. ..
